title: Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
authors.forename: W M
authors.initials: WM
authors.lastname: Castle
authors.forename: K
authors.initials: K
authors.lastname: Cunningham
authors.forename: B B
authors.initials: BB
authors.lastname: Kanarek
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D002945:Cisplatin / Q000009:adverse effects; D006801:Humans; D008787:Metoclopramide / Q000494:pharmacology; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced*; D013927:Thrombosis / Q000139:chemically induced*
chemical_list: D017294:Ondansetron; D008787:Metoclopramide; D002945:Cisplatin